Mesoblast Limited (MESO) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

16/25

Growth 5 Margin 5 Expansion 4 Platform 0 Financial 2

latest quarter score

Earnings Reports

16
Mesoblast (MESO) FY 2026: $115M Rioncel Launch Fuels Transition to Commercial Growth with Blockbuster Phase 3 Pipeline
August 27, 2026
19
Mesoblast (MESO) Q2 2026: Ryonsel Launch Drives $49M Revenue as Adult Label Expansion and BLA Filings Advance
February 28, 2026
15
Mesoblast (MESO) FY2025: Ryoncil® Launch Drives 191% Revenue Surge, Pivotal Adult Trials and Pipeline Progress Signal Growth Trajectory
August 28, 2025

Browse all companies